TherapeuticsMD, Inc.

How big is TherapeuticsMD, Inc.?

As of Jun 18, TherapeuticsMD, Inc. has a market capitalization of 12.96 million, categorizing it as a Micro Cap company, with net sales of 1.84 million and a net profit of -2.15 million over the latest four quarters. The company has shareholder's funds of 27.37 million and total assets of 38.82 million as of Dec 24.

Market Cap: As of Jun 18, TherapeuticsMD, Inc. has a market capitalization of 12.96 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 1.84 million and a net profit of -2.15 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company has shareholder's funds amounting to 27.37 million and total assets of 38.82 million.

What does TherapeuticsMD, Inc. do?

TherapeuticsMD, Inc. is a women's healthcare company specializing in hormone therapy pharmaceutical products. It has a market cap of $12.96 million and reported net sales of $0 million with a net profit of -$1 million as of March 2025.

Overview:<BR>TherapeuticsMD, Inc. is a women's healthcare company focused on creating and commercializing hormone therapy pharmaceutical products, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 12.96 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.18<BR>- Return on Equity: -2.93%<BR>- Price to Book: 0.48<BR><BR>Contact Details:<BR>- Address: 951 W Yamato Rd Ste 220, BOCA RATON FL : 33431-4440<BR>- Tel: 1 561 9611900<BR>- Website: https://www.therapeuticsmd.com/

Should I buy, sell or hold TherapeuticsMD, Inc.?

Who are in the management team of TherapeuticsMD, Inc.?

As of March 2022, the management team of TherapeuticsMD, Inc. includes Gov. Tommy Thompson (Independent Chairman), CEO Robert Finizio, and several independent directors: Paul Bisaro, J. Martin Carroll, Cooper Collins, Karen Ling, and Jules Musing. They oversee the company's strategic direction and operations.

As of March 2022, the management team of TherapeuticsMD, Inc. includes the following individuals:<BR><BR>- Gov. Hon. Tommy Thompson, Independent Chairman of the Board<BR>- Mr. Robert Finizio, Chief Executive Officer and Director<BR>- Mr. Paul Bisaro, Independent Director<BR>- Mr. J. Martin Carroll, Independent Director<BR>- Mr. Cooper Collins, Independent Director<BR>- Ms. Karen Ling, Independent Director<BR>- Mr. Jules Musing, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Is TherapeuticsMD, Inc. overvalued or undervalued?

As of November 12, 2024, TherapeuticsMD, Inc. is considered a risky investment due to its overvaluation indicated by poor financial metrics, including a Price to Book Value of 0.54, an EV to Sales ratio of 5.29, and a P/E ratio of -12.50, alongside a troubling 1-year stock return of -34.94% compared to the S&P 500's 17.14%.

As of 12 November 2024, the valuation grade for TherapeuticsMD, Inc. has moved from does not qualify to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 0.54 and an EV to Sales ratio of 5.29, which suggests that the market is pricing the company at a premium despite its poor performance. Additionally, the EV to EBITDA ratio stands at -3.66, reflecting significant operational challenges.<BR><BR>When compared to peers, TherapeuticsMD has a P/E ratio of -12.50, while Checkpoint Therapeutics, Inc. has a P/E of -6.58 and Journey Medical Corp. has a P/E of -18.70, highlighting that TherapeuticsMD is underperforming relative to its industry. The company's recent stock performance has been troubling, with a 1-year return of -34.94% compared to the S&P 500's 17.14%, reinforcing the notion that it is currently overvalued.

Is TherapeuticsMD, Inc. technically bullish or bearish?

As of September 8, 2025, TherapeuticsMD, Inc. shows a mildly bullish trend despite mixed technical indicators, having underperformed the S&P 500 recently but outperformed it year-to-date.

As of 8 September 2025, the technical trend for TherapeuticsMD, Inc. has changed from sideways to mildly bullish. The weekly MACD is bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The daily moving averages are mildly bullish, supporting the overall positive trend. However, the Bollinger Bands and KST on a weekly basis are bearish, and the OBV is mildly bearish on a monthly basis, suggesting some caution. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -2.70% and -5.26% compared to the S&P 500's 1.05% and 2.33%, respectively. However, year-to-date, the stock has outperformed the index with a return of 25.58% versus 12.22%. Overall, the current stance is mildly bullish, but the mixed indicators suggest a need for careful monitoring.